Duggan Robert W's Form 4 filing
Summit Therapeutics Inc. (SMMT) · filed Oct 23, 2025
- Accession no.
- 0001055919-25-000003
- Filed
- Oct 23, 2025
- Trade date
- Oct 21, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $500.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Duggan Robert WCIK 0001055919 | Director, Officer (Co-Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 21, 2025 | Common Stock | AGrant or awardAcquired | +13,980,789 | $18.74 | +$261,999,985.86 | 570,073,879 | Direct | |
| Oct 21, 2025 | Common Stock | AGrant or awardAcquired | +266,808 | $18.74 | +$4,999,981.92 | 25,724,474 | Indirect | |
| Oct 21, 2025 | Common Stock | PPurchaseAcquired | +26,680 | $18.74 | +$499,983.2 | 76,680 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.